Undergraduate Research Assistant Margo Waters (Sophomore), at her first poster presentation. Margo synthesizes the anisotropic nanoparticles being used in the ongoing study looking into the applications of antimicrobial peptides@nanoparticles as surfactants on implant materials and medical devices. The project lead is Dr. Juliane Hopf and her undergraduate mentee is Veronica Kalwatjys. The work is in collaboration …
Category Archive: Antimicrobial
NIH Funding Opportunities
- Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) November 22, 2024Funding Opportunity PAR-25-282 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an […]
- Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional) November 22, 2024Funding Opportunity PAR-25-281 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an […]
- Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed) November 22, 2024Funding Opportunity RFA-HL-26-020 from the NIH Guide for Grants and Contracts. The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent […]
- Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed) November 22, 2024Funding Opportunity RFA-HL-26-019 from the NIH Guide for Grants and Contracts. The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent […]
- Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed) November 22, 2024Funding Opportunity RFA-HL-26-018 from the NIH Guide for Grants and Contracts. The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent […]
- Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed) November 22, 2024Funding Opportunity RFA-HL-26-017 from the NIH Guide for Grants and Contracts. The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent […]
- Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt) (R61/R33 Clinical Trial Not Allowed) November 22, 2024Funding Opportunity RFA-AI-24-076 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support preclinical activities for the development of safe and effective long-acting/sustained release (LA/SR) technologies for prevention and treatment of HIV and HIV-associated tuberculosis (TB), hepatitis B (HBV) and hepatitis C (HCV), and to […]
- Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) November 22, 2024Funding Opportunity PAR-25-171 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National cancer Institute (NCI) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology […]
- Notice to Extend the Response Date for NOT-DK-24-026, "Request for Information (RFI): Research Strategies for Addressing Obesity Heterogeneity" November 22, 2024Notice NOT-DK-25-006 from the NIH Guide for Grants and Contracts
- Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed) November 22, 2024Funding Opportunity RFA-HL-26-016 from the NIH Guide for Grants and Contracts. The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent […]
Recent Comments